Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727105 | 1.00 | IDO1 (0.45) | IDO1POLQKDM4EKMT2AMAOB | |
| SCHEMBL13949606 | 0.86 | POLQ (0.44) | IDO1POLQKDM4EKMT2AMAOB | |
| SCHEMBL702504 | 0.82 | NPSR1 (0.47) | KDM4ENPSR1 | |
| SCHEMBL29616472 | 0.80 | POLQ (0.44) | POLQKDM4EKMT2AALDH1A1EPHX2 | |
| SCHEMBL18280121 | 0.80 | SRD5A2 (0.40) | IDO1POLQKMT2ANPSR1 | |
| SCHEMBL23148999 | 0.80 | POLQ (0.44) | POLQKDM4EKMT2AALDH1A1EPHX2 | |
| SCHEMBL13705083 | 0.79 | PPARG (0.41) | EPHX2PPARGSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24357851 | 0.79 | LMNA (0.38) | IDO1KMT2AEPHX2SLC6A4NPSR1 | |
| SCHEMBL4538982 | 0.78 | KCNH2 (0.43) | IDO1KDM4EALDH1A1NPSR1 | |
| SCHEMBL23119310 | 0.77 | STIM1 (0.37) | KDM4EKMT2AALDH1A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | IDO1 952/4885POLQ 2613/4885KDM4E 3899/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | IDO1 952/4885POLQ 2613/4885KDM4E 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.